Public note
For situational awareness and research transparency. Not medical advice.
System-generated assessment. This assessment remains under review until the stated horizon or until sufficient evidence allows evaluation.
Moderate confidence
The evidence is meaningful, but there is still material uncertainty. Based on 0 linked evidence items and assessed against 180D.
02
The criteria the system uses to determine whether this assessment is borne out by the stated horizon.
Method
The condition the system checks for when evaluating this assessment.
Minimum source quality
Evidence must meet or exceed this credibility tier to count toward evaluation.
Required terms
tecovirimatdocumentedtreatmenteuropean03
Tracking since Apr 21, 2026.
06
The current analyst narrative for this scope.
Clade Ib European multi-mode transmission ongoing; new research confirms MPXV replication in vaginal/ectocervical cells, strengthening non-sexual mucosal route concern.
No tecovirimat failure report in EU; long horizon
07
0 linked items.
No linked evidence is available for this assessment yet.
Integrity anchor
Brier 0.202
19 resolved novel pathogen detection predictions.